

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**絲路投資**

**Asia Pacific Silk Road Investment Company Limited**

**亞太絲路投資有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 767)**

**APPOINTMENT OF CHAIRMAN OF THE BOARD  
APPOINTMENT OF EXECUTIVE DIRECTOR  
AND  
APPOINTMENT OF HONORARY CHAIRMAN  
AND CHIEF SCIENTIST**

**APPOINTMENT OF CHAIRMAN OF THE BOARD AND APPOINTMENT OF EXECUTIVE DIRECTOR**

The Board is pleased to announce that with effect from 16 December 2020,

(i) Mr. YAN Li has been appointed as the Chairman of the Board; and

(ii) Ms. CAO XIE Qiong has been appointed as an Executive Director.

**APPOINTMENT OF HONORARY CHAIRMAN AND CHIEF SCIENTIST**

The Board is also pleased to announce that Academician Randy Wayne SCHEKMAN, a winner of the 2013 Nobel Prize in Physiology or Medicine, has been appointed as the Honorary Chairman and Chief Scientist of the Company with effect from 16 December 2020.

## **APPOINTMENT OF CHAIRMAN OF THE BOARD AND APPOINTMENT OF EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Asia Pacific Silk Road Investment Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that with effect from 16 December 2020, (i) Mr. YAN Li (“**Mr. Yan**”) has been appointed as the Chairman of the Board; and (ii) Ms. CAO XIE Qiong (“**Ms. Cao Xie**”) has been appointed as an Executive Director.

### **Mr. Yan, Chairman and Executive Director**

Mr. Yan, aged 49, was appointed as an Executive Director on 13 November 2020. He received the award of International Honorary Fellow of Greenville University in the United States in 2020. He is the vice president of Shenzhen Non-Governmental Organization Federation and was the vice president of Shenzhen General Chamber of Commerce. Mr. Yan has over 8 years’ experience in the management and administration in the fields of advanced medical and biological technology. In 2014, he founded Zhong Ji 1 International Medical Group (HK) Limited (“**HK Zhong Ji 1**”) and is currently a director and the chief executive officer of HK Zhong Ji 1. HK Zhong Ji 1 is dedicated to integrating leading resources about the health of knee joint around the globe and establishing the world’s leading international advanced medical transformation platform through cell testing, cell storage and enhancement, cell and gene therapies and the research and development, transformation and sale of biotechnology products. The Asian Integrated Cell Laboratory under HK Zhong Ji 1 is the world’s leading autoimmune cell bank. Currently, Mr. Yan is also a director of a subsidiary of the Company.

As at the date of this announcement, Mr. Yan holds, through his wholly- and beneficially-owned company, 90.76% shareholding interest in HK Zhong Ji 1, which in turn holds convertible notes issued by the Company in a principal amount of HK\$1,840,000,000, the conversion rights of which, if exercised in full, are convertible into 9,200,000,000 shares of the Company. Save as disclosed above, as at the date of this announcement, Mr. Yan has confirmed that he (i) does not have any relationship with any Director, senior management, or substantial or controlling shareholder (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) of the Company; (ii) does not have, and is not deemed to have, any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) does not hold any other directorship in the last three years in public companies, the securities of which are listed on any securities market in Hong Kong or overseas; and (iv) does not hold any other positions in the Group.

Pursuant to the appointment letter between the Company and Mr. Yan, Mr. Yan was not appointed for a specific or proposed term, and his appointment is subject to retirement by rotation and re-election (if applicable) at the annual general meeting at least once every three years in accordance with the bye-laws of the Company and the Corporate Governance Code set out in Appendix 14 to the Listing Rules. The remuneration of Mr.

Yan shall be determined by the remuneration committee of the Company and the Board and subject to annual review with reference to the prevailing market conditions, his duties and responsibilities, and the time spent on the affairs of the Company.

#### **Ms. Cao Xie, Executive Director**

Ms. Cao Xie, aged 52, holds a Master of Business Administration from the Business School of The Hong Kong University of Science and Technology and is an honorary professor of the College of Business & Public Management of Wenzhou-Kean University. She is a founding member of Hong Kong Professionals and Senior Executives Association and a member of the Zhejiang Provincial Committee of the Chinese People's Political Consultative Conference. She was a tourism ambassador for Zhejiang Province, a tourism spokesperson of Anhui Province, an overseas promotion ambassador for the Expo in Shanghai, a host at TVB in Hong Kong as well as a film and TV producer. She invested in the food and beverage industry in 2011 and was the brand director and group vice president of two listed companies. She entered the advanced biomedical technology sector in 2017 and is currently the executive chairperson of the Weissman Cancer Prevention Foundation.

As at the date of this announcement, Ms. Cao Xie has confirmed that she (i) does not have any relationship with any Director, senior management, or substantial or controlling shareholder (as defined in the Listing Rules) of the Company; (ii) does not have, and is not deemed to have, any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) does not hold any other directorship in the last three years in public companies, the securities of which are listed on any securities market in Hong Kong or overseas; and (iv) does not hold any other positions in the Group.

Pursuant to the appointment letter between the Company and Ms. Cao Xie, Ms. Cao Xie was not appointed for a specific or proposed term, and her appointment is subject to retirement by rotation and re-election (if applicable) at the annual general meeting at least once every three years in accordance with the bye-laws of the Company and the Corporate Governance Code set out in Appendix 14 to the Listing Rules. The remuneration of Ms. Cao Xie shall be determined by the remuneration committee of the Company and the Board and subject to annual review with reference to the prevailing market conditions, her duties and responsibilities, and the time spent on the affairs of the Company.

Save as disclosed above, there is no information in relation to the appointment of Mr. Yan as the Chairman of the Board and the appointment of Ms. Cao Xie as an executive Director that is required to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules, and there is no other matter that needs to be brought to the attention of the shareholders of the Company. The Company believes that both Mr. Yan and Ms. Cao Xie will make valuable contributions to the Group. The Board would like to extend its warmest welcome to Ms. Cao Xie for joining the Company.

## APPOINTMENT OF HONORARY CHAIRMAN AND CHIEF SCIENTIST

The Board is also pleased to announce that Academician Randy Wayne SCHEKMAN (“**Academician Schekman**”), a winner of the 2013 Nobel Prize in Physiology or Medicine, has been appointed as the Honorary Chairman and Chief Scientist of the Company with effect from 16 December 2020.

Academician Schekman, aged 71, is a profound cell biologist. He received a BA in Molecular Sciences from the University of California, Los Angeles in 1971 and received a doctorate in biochemistry in 1975 from Stanford University for research on DNA replication. He has been a member of the National Academy of Sciences since 1992, and was elected the President of the American Society for Cell Biology in 1999. He was the founding director of the Stem Cell Center of the University of California, Berkeley in 2015. He was former editor-in-chief of Proceedings of the National Academy of Sciences. In 2011, he was announced as the editor-in-chief of eLife, a high-profile open-access journal published by the Howard Hughes Medical Institute, the Max Planck Society and the Wellcome Trust launching in 2012. He shared the 2013 Nobel Prize for Physiology or Medicine with James Rothman and Thomas C. Südhof and received the Golden Plate Award of the American Academy of Achievement in 2017. Academician Schekman is currently the Chairman of Zhong Ji 1 International Medical Group (USA) and the President of World Life Sciences and Healthcare Association.

Academician Schekman is not a member of the Board, however, he shall report to the Board from time to time as and when required. The Board believes that Academician Schekman will make a valuable contribution to the Group and extends its warmest welcome to Academician Schekman for joining the Company.

By order of the Board  
**Asia Pacific Silk Road Investment Company Limited**  
**Yan Li**  
*Chairman*

Hong Kong, 16 December 2020

As at the date of this announcement, the Directors are:

*Executive Directors*

Mr. Yan Li (*Chairman*)

Mr. Yeung Siu Keung

Ms. Cao Xie Qiong

*Non-executive Director*

Ms. Yu Yang

*Independent non-executive Directors*

Mr. Wong Man Hong

Mr. Zheng Zhen

Mr. To Langa Samuelson

*In case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.*